Cargando…
Critical illness polyneuropathy, myopathy and neuronal biomarkers in COVID-19 patients: A prospective study
OBJECTIVE: The aim was to characterize the electrophysiological features and plasma biomarkers of critical illness polyneuropathy (CIN) and myopathy (CIM) in coronavirus disease 2019 (COVID-19) patients with intensive care unit acquired weakness (ICUAW). METHODS: An observational ICU cohort study in...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
International Federation of Clinical Neurophysiology. Published by Elsevier B.V.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8012169/ https://www.ncbi.nlm.nih.gov/pubmed/33875374 http://dx.doi.org/10.1016/j.clinph.2021.03.016 |
_version_ | 1783673325770244096 |
---|---|
author | Frithiof, Robert Rostami, Elham Kumlien, Eva Virhammar, Johan Fällmar, David Hultström, Michael Lipcsey, Miklós Ashton, Nicholas Blennow, Kaj Zetterberg, Henrik Punga, Anna Rostedt |
author_facet | Frithiof, Robert Rostami, Elham Kumlien, Eva Virhammar, Johan Fällmar, David Hultström, Michael Lipcsey, Miklós Ashton, Nicholas Blennow, Kaj Zetterberg, Henrik Punga, Anna Rostedt |
author_sort | Frithiof, Robert |
collection | PubMed |
description | OBJECTIVE: The aim was to characterize the electrophysiological features and plasma biomarkers of critical illness polyneuropathy (CIN) and myopathy (CIM) in coronavirus disease 2019 (COVID-19) patients with intensive care unit acquired weakness (ICUAW). METHODS: An observational ICU cohort study including adult patients admitted to the ICU at Uppsala University Hospital, Uppsala, Sweden, from March 13th to June 8th 2020. We compared the clinical, electrophysiological and plasma biomarker data between COVID-19 patients who developed CIN/CIM and those who did not. Electrophysiological characteristics were also compared between COVID-19 and non-COVID-19 ICU patients. RESULTS: 111 COVID-19 patients were included, 11 of whom developed CIN/CIM. Patients with CIN/CIM had more severe illness; longer ICU stay, more thromboembolic events and were more frequently treated with invasive ventilation for longer than 2 weeks. In particular CIN was more frequent among COVID-19 patients with ICUAW (50%) compared with a non-COVID-19 cohort (0%, p = 0.008). Neurofilament light chain (NfL) and glial fibrillary acidic protein (GFAp) levels were higher in the CIN/CIM group compared with those that did not develop CIN/CIM (both p = 0.001) and correlated with nerve amplitudes. CONCLUSIONS: CIN/CIM was more prevalent among COVID-19 ICU patients with severe illness. SIGNIFICANCE: COVID-19 patients who later developed CIN/CIM had significantly higher NfL and GFAp in the early phase of ICU care, suggesting their potential as predictive biomarkers for CIN/CIM. |
format | Online Article Text |
id | pubmed-8012169 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | International Federation of Clinical Neurophysiology. Published by Elsevier B.V. |
record_format | MEDLINE/PubMed |
spelling | pubmed-80121692021-04-01 Critical illness polyneuropathy, myopathy and neuronal biomarkers in COVID-19 patients: A prospective study Frithiof, Robert Rostami, Elham Kumlien, Eva Virhammar, Johan Fällmar, David Hultström, Michael Lipcsey, Miklós Ashton, Nicholas Blennow, Kaj Zetterberg, Henrik Punga, Anna Rostedt Clin Neurophysiol Article OBJECTIVE: The aim was to characterize the electrophysiological features and plasma biomarkers of critical illness polyneuropathy (CIN) and myopathy (CIM) in coronavirus disease 2019 (COVID-19) patients with intensive care unit acquired weakness (ICUAW). METHODS: An observational ICU cohort study including adult patients admitted to the ICU at Uppsala University Hospital, Uppsala, Sweden, from March 13th to June 8th 2020. We compared the clinical, electrophysiological and plasma biomarker data between COVID-19 patients who developed CIN/CIM and those who did not. Electrophysiological characteristics were also compared between COVID-19 and non-COVID-19 ICU patients. RESULTS: 111 COVID-19 patients were included, 11 of whom developed CIN/CIM. Patients with CIN/CIM had more severe illness; longer ICU stay, more thromboembolic events and were more frequently treated with invasive ventilation for longer than 2 weeks. In particular CIN was more frequent among COVID-19 patients with ICUAW (50%) compared with a non-COVID-19 cohort (0%, p = 0.008). Neurofilament light chain (NfL) and glial fibrillary acidic protein (GFAp) levels were higher in the CIN/CIM group compared with those that did not develop CIN/CIM (both p = 0.001) and correlated with nerve amplitudes. CONCLUSIONS: CIN/CIM was more prevalent among COVID-19 ICU patients with severe illness. SIGNIFICANCE: COVID-19 patients who later developed CIN/CIM had significantly higher NfL and GFAp in the early phase of ICU care, suggesting their potential as predictive biomarkers for CIN/CIM. International Federation of Clinical Neurophysiology. Published by Elsevier B.V. 2021-07 2021-04-01 /pmc/articles/PMC8012169/ /pubmed/33875374 http://dx.doi.org/10.1016/j.clinph.2021.03.016 Text en © 2021 International Federation of Clinical Neurophysiology. Published by Elsevier B.V. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Article Frithiof, Robert Rostami, Elham Kumlien, Eva Virhammar, Johan Fällmar, David Hultström, Michael Lipcsey, Miklós Ashton, Nicholas Blennow, Kaj Zetterberg, Henrik Punga, Anna Rostedt Critical illness polyneuropathy, myopathy and neuronal biomarkers in COVID-19 patients: A prospective study |
title | Critical illness polyneuropathy, myopathy and neuronal biomarkers in COVID-19 patients: A prospective study |
title_full | Critical illness polyneuropathy, myopathy and neuronal biomarkers in COVID-19 patients: A prospective study |
title_fullStr | Critical illness polyneuropathy, myopathy and neuronal biomarkers in COVID-19 patients: A prospective study |
title_full_unstemmed | Critical illness polyneuropathy, myopathy and neuronal biomarkers in COVID-19 patients: A prospective study |
title_short | Critical illness polyneuropathy, myopathy and neuronal biomarkers in COVID-19 patients: A prospective study |
title_sort | critical illness polyneuropathy, myopathy and neuronal biomarkers in covid-19 patients: a prospective study |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8012169/ https://www.ncbi.nlm.nih.gov/pubmed/33875374 http://dx.doi.org/10.1016/j.clinph.2021.03.016 |
work_keys_str_mv | AT frithiofrobert criticalillnesspolyneuropathymyopathyandneuronalbiomarkersincovid19patientsaprospectivestudy AT rostamielham criticalillnesspolyneuropathymyopathyandneuronalbiomarkersincovid19patientsaprospectivestudy AT kumlieneva criticalillnesspolyneuropathymyopathyandneuronalbiomarkersincovid19patientsaprospectivestudy AT virhammarjohan criticalillnesspolyneuropathymyopathyandneuronalbiomarkersincovid19patientsaprospectivestudy AT fallmardavid criticalillnesspolyneuropathymyopathyandneuronalbiomarkersincovid19patientsaprospectivestudy AT hultstrommichael criticalillnesspolyneuropathymyopathyandneuronalbiomarkersincovid19patientsaprospectivestudy AT lipcseymiklos criticalillnesspolyneuropathymyopathyandneuronalbiomarkersincovid19patientsaprospectivestudy AT ashtonnicholas criticalillnesspolyneuropathymyopathyandneuronalbiomarkersincovid19patientsaprospectivestudy AT blennowkaj criticalillnesspolyneuropathymyopathyandneuronalbiomarkersincovid19patientsaprospectivestudy AT zetterberghenrik criticalillnesspolyneuropathymyopathyandneuronalbiomarkersincovid19patientsaprospectivestudy AT pungaannarostedt criticalillnesspolyneuropathymyopathyandneuronalbiomarkersincovid19patientsaprospectivestudy |